Jiangsu Simcere registers Phase II/III trial of SIM0811 in acute ischemic stroke
Planned enrollment is 1092 participants and the study is expected to start on November 30, 2026, with primary completion projected for June 30, 2029. Researchers will compare different doses of SIM0811 to a placebo in patients treated within 4.5 to 24 hours after last known well.
Primary source
ClinicalTrials.gov registry record, October 29, 2026
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
Read the source: A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation